GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...
The Financial Times2d
GSK’s ex-vaccines chief says its jab for a flu-like virus is too expensive
The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...
GlobalData on MSN1d
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...
'A really serious respiratory virus:' What you need to know about RSV and new vaccines
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
cilisos.my20h
GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Managed Healthcare Executive2d
RSV Vaccine Keeps Older People Out of the Hospital
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
BioSpace5d
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...
FiercePharma6d
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
Malaysiakini12h
GSK's respiratory syncytial virus vaccine approved in M'sia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...